GKOS
NYSE
$153.15
Glaukos Corporation (GKOS)
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Sector:
Healthcare
Industry:
Medical Devices
Strong Buy
Target: $165 (+7.74%)
Market Cap
$9.15B
Free Cash Flow Yield
-0.20%
Beta (5Y)
1.30
Price Chart
Valuation
Market Cap$9.15B
Forward P/E2000.00
P/S16.24
P/B13.37
Profitability
Total Revenue (TTM)$551M
Gross Profit (TTM)$431M
EBITDA-$157M
Profit Margin-13.1%
Operating Margin-13.2%
EPS-$3.29
Financial Health
Free Cash Flow Yield-0.20%
Growth & Risk
EPS 5Y CAGR+12.32%
Revenue 5Y CAGR+18.34%
FCF 5Y CAGR-8.65%
Beta (5Y)1.30
Sharpe Ratio1.04